Patient Stratification in Ulcerative Colitis
Ulcerative Colitis
Key Facts
About Enable Medicine
Enable Medicine is a private, AI-driven digital health company founded in 2019, operating as a platform and services provider in the biotech sector. The company has developed a comprehensive cloud platform that indexes and analyzes vast amounts of multimodal biological data, such as spatial proteomics and single-cell data, to answer critical research questions in areas like patient stratification and target identification. It collaborates with over 200 entities in biopharma and academia, has indexed data from 60,000+ samples, and has been featured in 75+ published studies. Enable Medicine is in an early revenue stage, monetizing its AI-powered analysis platform and scientific services to accelerate therapeutic R&D for its partners.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |
| '1805 | Revolo Biotherapeutics | Phase 2 (Planned) |